All In Biotech

Drug Trial Radar · NCT02980679

A Study to Compare the Safety and Imaging Pattern of Cyclotron-produced Technetium (CTC) vs. Generator-produced Technetium (G-PERT) in People With Thyroid Disorders Who Need Surgery

A Pivotal Phase III Study of Cyclotron-produced Tc-99m Pertechnetate (CTC) Compared to Generator-produced Tc-99m Pertechnetate (G-PERT) in Subjects With Thyroid Disorders

Last checked: Nov 19, 2026Latest source record: Apr 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Title says "pivotal". This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

25

Actual

Start

Mar 3, 2017

Primary completion

Feb 25, 2019

Study completion Feb 25, 2019

Sponsor

Lead sponsor
University of AlbertaAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 2, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A 99mTc Pertechnetate (G-PERT) scan is a nuclear medicine test that can create an image of the thyroid gland and other organs. G-PERT is approved by Health Canada for the direct imaging and measurement of thyroid uptake. Doctors and researchers at the University of Alberta have developed a new method of producing 99mTc Pertechnetate (called CTC). It is made in a cyclotron at the Medical Isotope and Cyclotron Facility (MICF) at the University of Alberta, Edmonton, Alberta. This new production method will provide another source of 99mTc Pertechnetate. The aim of this study is to confirm that CTC is safe and can be used interchangeably with G-PERT.

Conditions

  • Thyroid Gland Diseases

Interventions

  • CTCDrug

    After injection of CTC, a whole body and thyroid scan will be performed.

  • G-PERTDrug

    After injection of G-PERT, a whole body and thyroid scan will be performed.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical Comparability of CTC with G-PERTTime frame: up to 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cross Cancer Institute

    Edmonton, Alberta, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.